Sernova Cell Pouch System
SernovaThe Sernova Cell Pouch System is a revolutionary product that provides an implantable medical device for therapeutic cells. It offers a cutting-edge solution for diabetes treatment by enabling the long-term survival and function of insulin-producing cells. The unique design of the Cell Pouch System promotes vascularization, enhancing the cell engraftment and function. Sernova's technology stands out in the market due to its potential to improve the quality of life for patients with chronic diseases like diabetes.
$10,000-20,000 in Canada
ViaCyte PEC-Encap
ViaCyteViaCyte's PEC-Encap is a top-tier product in the field of regenerative medicine for diabetes. The PEC-Encap device encapsulates stem cell-derived pancreatic progenitor cells, offering a potentially curative treatment for diabetes. This innovative approach to cell replacement therapy sets ViaCyte apart from its competitors. With its ability to mimic the natural pancreas function, the PEC-Encap holds promise for transforming the treatment landscape for diabetes patients.
$15,000-25,000 in Canada
Beta-O2 Bio Technologies Beta-O2
Beta-O2 Bio TechnologiesBeta-O2 Bio Technologies' Beta-O2 system represents a breakthrough in bio-artificial pancreas technology. The device encapsulates insulin-producing cells within a protective membrane, providing a sustainable and functional solution for diabetes management. By offering a unique combination of immunoisolation and oxygen supply, the Beta-O2 system ensures enhanced cell viability and therapeutic efficacy. Beta-O2's product stands out for its potential to revolutionize the way diabetes is treated, offering hope for improved patient outcomes.
$20,000-30,000 in Canada
CRISPR Therapeutics CTX001
CRISPR TherapeuticsCRISPR Therapeutics' CTX001 is a game-changing product in the realm of gene editing therapies for blood disorders like beta thalassemia and sickle cell disease. The CTX001 treatment involves modifying patients' own hematopoietic stem cells to produce functional hemoglobin, addressing the underlying genetic cause of these conditions. With its precision and efficiency, CTX001 sets a new standard in gene therapy and holds significant promise for patients with blood disorders. CRISPR Therapeutics is at the forefront of genetic medicine innovation with the development of CTX001.
$30,000-40,000 in Canada
Sigilon Therapeutics Encaptra
Sigilon TherapeuticsSigilon Therapeutics' Encaptra is a cutting-edge product that combines advanced cell engineering and immune protection technologies. The Encaptra device encapsulates therapeutic cells to shield them from immune rejection and prolong their survival in the body. By offering a versatile platform for multiple therapeutic applications, Sigilon's technology stands out for its potential to transform the field of cell-based therapies. With its focus on delivering long-lasting and effective treatments, the Encaptra holds promise for addressing a range of diseases and improving patient outcomes.
$25,000-35,000 in Canada